Options Bulls Could Be Right About This Pharma Stock

Insmed Inc (NASDAQ:INSM) shares were last seen up 0.3% to trade at $164.03, after a price-target hike to $237 from $231 at Barclays. The pharmaceutical stock is on track for its third-straight daily gain and just wrapped up its best month since November, but also saw its first quarterly loss since 2024. Though the equity carries a 6.2% deficit for 2026, a bullish trendline is now flashing, which may help distance the shares from their March underperformance.

The trendline in question is the stock's 80-day moving average. Per Schaeffer's Senior Quantitative Analyst Rocky White, this “crossover” event happened 17 other times over the last 10 years, after which the security was higher one month later 59% of the time, averaging a 5.4% gain. From its current perch, a comparable move would put INSM above $173 for the first time since January.

Options traders are overwhelmingly bullish. This is per INSM's 10-day call/put volume ratio of 64.74 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) that sits higher than 98% of annual readings.

Options look like an attractive route when weighing on the stock's next moves, per its Schaeffer's Volatility Index (SVI) of 43% that sits higher than 12% of readings from the past year. In other words, near-term option traders are now pricing in low volatility expectations.

Plus, the equity's Schaeffer's Volatility Scorecard (SVS) comes in at an elevated 83 out of 100. This means the shares have consistently realized higher volatility than the options have priced in over the past 12 months.